Reduction in Mortality Associated with Statin Therapy in Patients with Severe Sepsis

被引:69
作者
Dobesh, Pan P. [1 ]
Klepser, Donald G. [1 ]
McGuire, Timothy R. [1 ]
Morgan, Craig W. [1 ]
Olsen, Keith M. [1 ]
机构
[1] Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE 68198 USA
来源
PHARMACOTHERAPY | 2009年 / 29卷 / 06期
关键词
sepsis; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; statins; critical care; intensive care unit; ICU; inflammation; mortality; DYSFUNCTION; PATHOPHYSIOLOGY; INFLAMMATION; DEFINITIONS; ADMISSION; INFECTION; EFFICACY; SAFETY;
D O I
10.1592/phco.29.6.621
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To evaluate the effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) on mortality ill patients Mill severe sepsis. Design. Retrospective cohort study. Setting. Intensive Care Unit (ICU) of an academic medical center. Patients. One hundred eighty-eight patients aged 40 years or older with a diagnosis of severe sepsis and an ICU stay between January 2005, mid December 31, 2006. Measurements and Main Results. Patient demographic data, statin use, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores at the time of sepsis diagnosis were collected from the patient database. We used a multivariable logistic regression model to evaluate the association between statin use and in-hospital all-cause mortality after controlling for age, sex, and severity of illness. Of the 188 patients who met our inclusion criteria, 60 (32%) had statin exposure. Patients receiving statins were similar in age, sex, and APACHE II scores to those not receiving statins. In the univariable comparison, the statin group had a 35%, relative reduction in mortality compared with the nonstatin group (mortality rate 31.7% vs 48.4%, p=0.040). Most of the mortality reduction attributed to statins occurred hi patients with APACHE II scores higher than 24 (mortality rate 32.3% vs 57.5%, p=0.030, with a minimal mortality difference in patients with APACHE II scores of 24 or lower (31% vs 36.4%, p=0.810). In the multivariable regression model, statin use had a protective effect (odds ratio [OR] 0.42, 95% confidence interval [CI] 0.21-0-84, p=0.014), whereas increasing age (OR 1.03, 95% CI 1.01-1.06, p=0.013) and higher APACHE II score (OR.1.11, 95% CI 1.05-1.18, p=0.00.1) were associated with increased mortality. Conclusion. The use of statins was associated with a protective effect ill patients with severe sepsis, as demonstrated by a significant. reduction ill mortality compared with patients not receiving statins.
引用
收藏
页码:621 / 630
页数:10
相关论文
共 32 条
[1]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[2]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[3]   Statins, inflammation, and sepsis - Hypothesis [J].
Almog, Y .
CHEST, 2003, 124 (02) :740-743
[4]   Prior statin therapy is associated with a decreased rate of severe sepsis [J].
Almog, Y ;
Shefer, A ;
Novack, V ;
Maimon, N ;
Barski, L ;
Eizinger, M ;
Friger, M ;
Zeller, L ;
Danon, A .
CIRCULATION, 2004, 110 (07) :880-885
[5]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[6]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[7]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[8]   The endothelium, inflammation, and coagulation in sepsis [J].
Boos, CJ ;
Goon, PKY ;
Lip, GYH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (01) :20-22
[9]   Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation [J].
Chenaud, C ;
Merlani, PG ;
Roux-Lombard, P ;
Burger, D ;
Harbarth, S ;
Luyasu, S ;
Graf, JD ;
Dayer, JM ;
Ricou, B .
CRITICAL CARE MEDICINE, 2004, 32 (03) :632-637
[10]  
Clunn G, 2000, LANCET, V356, P2097, DOI 10.1016/S0140-6736(05)74306-3